EIN: 464099785
UEI: RDMJC6RVJD54
Data as of August 26, 2026
Management decision deadline — for entities that funded this organization
The FAC accepted this audit on July 1, 2026. Under 2 CFR 200.521(d), a pass-through entity that provided federal funds to this organization for this audit period must issue a management decision on these findings by January 1, 2027 (127 days from today).
What is a management decision? →Contracts with subrecipients did not include portions of required disclosures. Cause/Effect: Inadequate internal controls over compliance. Select contracts were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the PIHP update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
Show full finding ▾Hide full finding ▴2025-001 – Communications with Subrecipients Finding Type: Significant Deficiency in internal control over compliance / noncompliance Program: ALN 93.788 – State Opioid Response Criteria: As required by 2 CFR 200.332, the pass-through entity must communicate specific information to subrecipients, as applicable. Condition: Contracts with subrecipients did not include portions of required disclosures. Cause/Effect: Inadequate internal controls over compliance. Select contracts were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the PIHP update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
June 12, 2026 Response to Single Audit Finding 2025-001 Finding: Program: ALN 93.788 – State Opioid Response Criteria: As required by 2 CFR 200.332, the pass-through entity must communicate specific information to subrecipients, as applicable. Condition: Contracts with subrecipients did not include portions of required disclosures. Cause/Effect: Inadequate internal controls over compliance. Select contracts were not in compliance with 2 CFR 200.332. Management agrees with this finding and has already implemented measures to ensure that it is not repeated. The additional step of having the Finance Department review contracts with federal dollars to ensure that the ALN in the contract is consistent with the ALN on the contract award. This policy is in place as of June 12, 2026. Matt Berg is responsible for implementing this corrective action.
FAC accepted this audit on June 21, 2024 — management decision was due December 21, 2024.
Contracts with subrecipients did not include portions of required disclosures. Cause/Effect: Inadequate internal controls over compliance. Select contracts were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the PIHP update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
Show full finding ▾Hide full finding ▴2023-001 – Communications with Subrecipients (repeat comment) Finding Type: Significant Deficiency in internal control over compliance / noncompliance Program: ALN 93.959 – COVID-19 - ARPA Treatment Criteria: As required by 2 CFR 200.332, the pass-through entity must communicate specific information to subrecipients, as applicable. Condition: Contracts with subrecipients did not include portions of required disclosures. Cause/Effect: Inadequate internal controls over compliance. Select contracts were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the PIHP update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
Corrective Action Plan Finding: 2023-001 – Communications with Subrecipients (repeat comment) Condition: Contracts with subrecipients did not include portions of required disclosures. Corrective Action Plan: CMHPSM added an additional staff position, Regional Project Assistant, to do additional work on contracts. This position was added after the April 2023 Board meeting to assist with contract reviews. The position reports up to CJ Witherow.
2022-001
FAC accepted this audit on June 26, 2023 — management decision was due December 26, 2023.
During testing of contracts with subrecipients it was noted that these contracts did not include portions of required disclosures. Cause/Effect: This condition appears to be the result of inconsistent application of internal controls over compliance. Contracts with subrecipients were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the Entity update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
Show full finding ▾Hide full finding ▴2022-001: Considered a significant deficiency in internal control over compliance/immaterial non-compliance Program: ALN 93.958 Block Grants for Prevention and Treatment of Substance Abuse (Treatment and Access Management) Criteria: As detailed by 2 CFR 200.332, the pass-through entity must communicate specific information to subrecipients, as applicable. Condition: During testing of contracts with subrecipients it was noted that these contracts did not include portions of required disclosures. Cause/Effect: This condition appears to be the result of inconsistent application of internal controls over compliance. Contracts with subrecipients were not in compliance with 2 CFR 200.332. Questioned Cost: None. Recommendation: We recommend that the Entity update all contracts with subrecipients to include required language. View of Responsible Official: Management is in agreement with this recommendation.
FY 2022 CMHPSM Single Audit Findings Response Finding 2022-001: Considered a significant deficiency in internal control over compliance/immaterial non-compliance Program: ALN 93.959 Block Grants for Prevention and Treatment of Substance Abuse (Treatment and Access Management) Condition: During testing of contracts with subrecipients it was noted that these contracts did not include portions of required disclosures. Corrective Action: CMHPSM will revise all contracts that disburse Block Grant Funds so that they include that the recipient is a subrecipient and include the grant number. Matt Berg and CJ Witherow are responsible for implementing this change. The change to be complete by August 31, 2023.
During testing it was noted that $112,581 of costs that were allowable under COVID-19 - ARPA Treatment were incorrectly allocated from COVID-19 - ARPA Treatment to ARPA Prevention. Cause/Effect: This condition appears to be a breakdown of communication between members of the entity?s staff relating to the allowability of costs under different grants. Questioned Cost: $112,581 Recommendation: We recommend that the Entity review its methods for communicating among its staff to ensure that staff appropriately understand the allowability of costs under each grant. View of Responsible Official: Management is in agreement with this recommendation.
Show full finding ▾Hide full finding ▴2022-002: Considered a significant deficiency in internal control over compliance/immaterial non-compliance Program: ALN 93.959 Block Grants for Prevention and Treatment of Substance Abuse (COVID-19 - ARPA Prevention) Criteria: As detailed by 2 CFR 200.309, ?A non-Federal entity may charge to the Federal award only allowable costs incurred during the period of performance and any costs incurred before the Federal awarding agency or pass-through entity made the Federal award that were authorized by the Federal awarding agency or pass-through entity.?. Condition: During testing it was noted that $112,581 of costs that were allowable under COVID-19 - ARPA Treatment were incorrectly allocated from COVID-19 - ARPA Treatment to ARPA Prevention. Cause/Effect: This condition appears to be a breakdown of communication between members of the entity?s staff relating to the allowability of costs under different grants. Questioned Cost: $112,581 Recommendation: We recommend that the Entity review its methods for communicating among its staff to ensure that staff appropriately understand the allowability of costs under each grant. View of Responsible Official: Management is in agreement with this recommendation.
Finding 2022-002: Considered a significant deficiency in internal control over compliance/immaterial non-compliance Program: ALN 93.959 Block Grants for Prevention and Treatment of Substance Abuse (ARPA Prevention) Criteria: As detailed by 2 CFR 200.309, ?A non-Federal entity may charge to the Federal award only allowable costs incurred during the period of performance and any costs incurred before the Federal awarding agency or pass-through entity made the Federal award that were authorized by the Federal awarding agency or pass-through entity.?. Condition: During testing it was noted that $112,581 of costs that were allowable under ARPA Treatment were incorrectly allocated from ARPA Treatment to ARPA Prevention. Corrective Action: All finance staff responsible for any allocation of grant funding have undergone additional training or reading on how to allocate grants. The was completed by April 30, 2023.
FAC accepted this audit on December 29, 2020 — management decision was due June 29, 2021.
The final financial status report for this grant included costs that were also charged to, and reimbursed by, another grant. Cause/Effect: This condition appears to be the result of a failure to move expenses to the proper funding source prior to requested reimbursement. Questioned Cost: $47,227.00 Recommendation: We recommend that the Entity ensure that all requests for reimbursement are supported by costs that are chargeable to the grant and recorded in a detailed general ledger that tracks expenses for that grant. In addition, the Entity should adopt and implement procedures to ensure that costs are only charged to one funding source/grant. View of Responsible Official: Management is in agreement with this recommendation
Show full finding ▾Hide full finding ▴2019-001: CASH MANAGEMENT Type: Immaterial Noncompliance Program: CFDA #93.788 Opioid STR Criteria: Per 2 CFR 200.403(f), expenses shall, ?not be included as a cost or used to meet cost sharing or matching requirements of any other federally-funded programs in either the current or a prior period?. Condition: The final financial status report for this grant included costs that were also charged to, and reimbursed by, another grant. Cause/Effect: This condition appears to be the result of a failure to move expenses to the proper funding source prior to requested reimbursement. Questioned Cost: $47,227.00 Recommendation: We recommend that the Entity ensure that all requests for reimbursement are supported by costs that are chargeable to the grant and recorded in a detailed general ledger that tracks expenses for that grant. In addition, the Entity should adopt and implement procedures to ensure that costs are only charged to one funding source/grant. View of Responsible Official: Management is in agreement with this recommendation
Finding 2019-001 CASH MANAGEMENT Management agrees with this finding and has already implemented a policy where the person who enters the activity is not the person who submits the request for reimbursement. The person who submits the grants does so from a report that lists all allowable costs for the grant period and divides them into the applicable grant. This process will prevent any future charging of expenses to multiple grants. Matt Berg, CFO, was responsible for implementing this plan which was completed August 1, 2020.
During test we noted that $66.24 was charged to the grant for prior year costs. Cause/Effect: This condition appears to be the result of an effort to clear a prior year balance sheet account to various expense line items. Questioned Cost: $66.24 Recommendation: We recommend that the Entity adopt and implement procedures to ensure that costs charged to a grant are for the approved budget period only. View of Responsible Official: Management is in agreement with this recommendation.
Show full finding ▾Hide full finding ▴2019-002: ACTIVITIES ALLOWED/ALLOWABLE COSTS/PERIOD OF PERFORMANCE Type: Immaterial Noncompliance Program: CFDA #93.788 Opioid STR Criteria: Per 2 CFR 200.403(h), ?Costs must be incurred during the approved budget period.? Condition: During test we noted that $66.24 was charged to the grant for prior year costs. Cause/Effect: This condition appears to be the result of an effort to clear a prior year balance sheet account to various expense line items. Questioned Cost: $66.24 Recommendation: We recommend that the Entity adopt and implement procedures to ensure that costs charged to a grant are for the approved budget period only. View of Responsible Official: Management is in agreement with this recommendation.
Finding 2019-002 ACTIVITIES ALLOWED/ALLOWABLE COSTS/PERIOD OF PERFORMANCE Management agrees with his finding and has implemented a policy of reviewing all costs allocated to grants including a review of the dates of activity. No expenses are allowed for prior year activities. Accounts are reconciled on a monthly basis to ensure that costs only appear in the approved budget period. Matt Berg, CFO, was responsible for implementing this plan which was completed August 1, 2020.
Data source: This information comes from the Federal Audit Clearinghouse, the official repository of Single Audit data. All data is public domain. Verify this organization's audit history at fac.gov.
Track your findings and corrective action plans across audit cycles.
Start tracking findings →Monitor subrecipient audit findings and compliance status.
Start monitoring →© 2026 Single Audit Intelligence. All data is public domain.